Literature DB >> 26815235

Serum cleaved tau protein and traumatic mild head injury: a preliminary study in the Thai population.

P Wuthisuthimethawee1, S Saeheng2, T Oearsakul2.   

Abstract

PURPOSE: To determine the correlation between serum cleaved tau protein and traumatic mild head injury (MHI) (GCS 13-15).
METHODS: A prospective observational study was conducted. Blood specimens from 12 healthy persons and 44 adult patients with traumatic MHI were collected in the emergency department to measure the cleaved tau protein level using a Human Tau phosphoSerine 396 ELISA kit. A brain computed tomography (CT) scan was done in all patients. The serum cleaved tau protein level was considered positive at a cut-off point of 0.1 pg/ml. An intracranial lesion was defined as any abnormality detected by brain CT scan.
RESULTS: The mean age of the traumatic MHI patients was 34.9 ± 15.6 years (range 15-74). The median GCS was 15. The median time from injury to arrival at the emergency department was 30 min. There were 11 intracranial lesions detected by brain CT scan (25.0 %). Serum cleaved tau protein was not detected in either healthy or traumatic MHI patients.
CONCLUSION: As it was uncorrelated with traumatic MHI, serum cleaved tau protein proved to be an unreliable biomarker to use in the early detection of and decision-making for traumatic MHI patients at the emergency department.

Entities:  

Keywords:  Biomarker; Emergency department; Serum cleaved tau protein; Traumatic mild head injury

Year:  2013        PMID: 26815235     DOI: 10.1007/s00068-013-0263-9

Source DB:  PubMed          Journal:  Eur J Trauma Emerg Surg        ISSN: 1863-9933            Impact factor:   3.693


  26 in total

1.  Validity of serum tau protein levels in pediatric patients with minor head trauma.

Authors:  Ahmet Guzel; Serap Karasalihoglu; Hakan Aylanç; Osman Temizöz; Tufan Hiçdönmez
Journal:  Am J Emerg Med       Date:  2010-01-28       Impact factor: 2.469

Review 2.  Clinical decision rules for adults with minor head injury: a systematic review.

Authors:  Sue E Harnan; Alastair Pickering; Abdullah Pandor; Steve W Goodacre
Journal:  J Trauma       Date:  2011-07

3.  Serum markers of brain damage and outcome prediction in patients after severe head injury.

Authors:  A Raabe; C Grolms; V Seifert
Journal:  Br J Neurosurg       Date:  1999-02       Impact factor: 1.596

4.  Cleaved-tau: a biomarker of neuronal damage after traumatic brain injury.

Authors:  S Prasad Gabbita; Stephen W Scheff; Renee M Menard; Kelly Roberts; Isabella Fugaccia; Frank P Zemlan
Journal:  J Neurotrauma       Date:  2005-01       Impact factor: 5.269

Review 5.  Serum biochemical markers for post-concussion syndrome in patients with mild traumatic brain injury.

Authors:  Tomer Begaz; Demetrios N Kyriacou; Jordana Segal; Jeffrey J Bazarian
Journal:  J Neurotrauma       Date:  2006-08       Impact factor: 5.269

6.  Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury.

Authors:  M Ost; K Nylén; L Csajbok; A Olsson Ohrfelt; M Tullberg; C Wikkelsö; P Nellgård; L Rosengren; K Blennow; B Nellgård
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

7.  Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury.

Authors:  C Woertgen; R D Rothoerl; C Metz; A Brawanski
Journal:  J Trauma       Date:  1999-12

8.  The value of serum tau protein for the diagnosis of intracranial injury in minor head trauma.

Authors:  Cemil Kavalci; Murat Pekdemir; Polat Durukan; Necip Ilhan; Mustafa Yildiz; Selami Serhatlioglu; Dilara Seckin
Journal:  Am J Emerg Med       Date:  2007-05       Impact factor: 2.469

9.  Tau protein in the cerebrospinal fluid is a marker of brain injury after aortic surgery.

Authors:  Norihiko Shiiya; Takashi Kunihara; Tsukasa Miyatake; Kenji Matsuzaki; Keishu Yasuda
Journal:  Ann Thorac Surg       Date:  2004-06       Impact factor: 4.330

10.  Quantification of post-concussion symptoms 3 months after minor head injury in 100 consecutive patients.

Authors:  T Ingebrigtsen; K Waterloo; S Marup-Jensen; E Attner; B Romner
Journal:  J Neurol       Date:  1998-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.